NASH development strategy for tesamorelin to be unveiled on June 17, 2019
MONTREAL, June 14, 2019 — Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce additional data from the recently completed study funded by the National Institutes of Health, led by Dr. Steve Grinspoon, and conducted at the Massachusetts General Hospital and Harvard Medical School and the National Institutes of Health.
New data from the study show a statistically significant difference in the progression of fibrosis for patients in the tesamorelin arm. In the tesamorelin group, only 10.5% of patients experienced progression of liver fibrosis compared to 37.5% in patients receiving a placebo (p=0.04).
In addition, previously released data showed that in patients on tesamorelin, liver fat decreased by 32% while it increased by 5% in placebo patients, from baseline, (p=0.02), amounting to a 37% relative reduction in liver fat. Furthermore, 35% of patients in the tesamorelin group returned to liver fat values below 5% in comparison to only 4% of patients on placebo (p=0.007).
“Results obtained in this study are consistent with effects on ectopic fat depots observed in other tesamorelin trials over the last 12 years. Based on these results, tesamorelin represents a potentially promising option for the treatment of NAFLD/NASH in people living with HIV,” said Dr. Steve Grinspoon, Professor of Medicine, Harvard Medical School, and Chief of the Metabolism Unit, Mass General Hospital.
“The fact that we were able to show a statistically significant difference in the progression of fibrosis in a limited number of patients, along with the previously announced data on the effect of tesamorelin on liver fat in HIV patients is very encouraging”, commented Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer, Theratechnologies Inc.
The 12-month randomized, double-blind, placebo-controlled clinical trial enrolled a total of 61 men and women with HIV infection and hepatic fat fraction ≥5%, assessed by magnetic resonance spectroscopy; 31 patients were randomized in the tesamorelin group while 30 patients were enrolled in the placebo group. At baseline, patients enrolled in the study had hepatic fat levels of 13.8%. In total, 43% of patients had fibrosis as assessed by liver biopsies.
“Given the strong evidence coming from this study, we are now in a position to share our strategic approach for the development of tesamorelin for the potential treatment of NASH in people living with HIV,” said Luc Tanguay, President and Chief Executive Officer, Theratechnologies Inc. “We look forward to sharing our development plan with investors and analysts, on Monday, June 17, 2019”, concluded Mr. Tanguay.
Conference Call and Webcast Details
A conference call and webcast will be held Monday, June 17, 2019 at 8:30 a.m. (ET) to discuss the results and present the development strategy. The conference call will be open to questions from financial analysts. Media and other interested individuals are invited to participate in the call on a “listen-only” basis.
The conference call can be accessed by dialling 1-877-223-4471 (North America) or 1-647-788-4922 (International). The presentation will be accessible at https://event.on24.com/wcc/r/2027396-1/F122106742BE84353727FCBD14FE563A. Audio replay of the conference call will be available on the same day starting at 11:30 a.m. (ET) until August 18, 2019, by dialling 1-800-585-8367 (North America) or 1-416-621-4642 (International) and by entering the playback code 1894634.
Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including those living with HIV. Further information about Theratechnologies is available on the Company’s website at www.theratech.com and on SEDAR at www.sedar.com.